NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
Authors
Baldini, C.Patnaik, A.
Lakhani, N.
Call, J.
Galsky, M.
Garmezy, B.
Wei, A.
Carter, Louise
Powles, T.
Siefker-Radtke, A.
O'Donnell, P. H.
Kitano, S.
Castellano, D. E.
Shinde, R.
Joshua, A. M.
Balbas, M.
Han, H.
Chang, A. E.
Gao, X.
Iyer, G.
Affiliation
The University of Manchester and The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Baldini C, Patnaik A, Lakhani N, Call J, Galsky M, Garmezy B, et al. NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress). EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S66-S. PubMed PMID: WOS:001345547300158. English.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114686Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114686Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114686